Ehab L. Atallah
Expertise in
25
conditions

Dr. Ehab L. Atallah

Hematology | Oncology
8800 W. Doyne Ave., 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
23 Years of Experience
Expertise in
25
conditions
8800 W. Doyne Ave., 
Milwaukee, WI 

Overview

Ehab Atallah, MD, is a Professor of Medicine and Associate director of the cancer service line in the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia, myelodysplastic syndromes, myeloproliferative neoplasms and other bone marrow failure disorders at Froedtert Hospital. He graduated from Cairo University School of Medicine in 1994, then completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. He then went on to complete a leukemia fellowship at M.D. Anderson Cancer Center in Houston, Texas. Dr. Atallah is board certified/eligible in Internal Medicine, Medical Oncology, and Hematology. He has authorednumerous publications, including journal articles, meeting abstracts, and book chapters. His current research interests are treatment of patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, myeloproliferative neoplasms and myelodysplastic syndromes. He currently serves as the co-chair of the Eastern Cooperative Group (ECOG) leukemia committee. He is the administrative director of the H Jean Khoury Cure CML Consortium (HJKC3). The HJKC3 was established in 2016 and is a collaborative effort of physicians and researchers at 21 academic medical centers committed to CML research and improving patient care and quality of life.

Dr. Atallah is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Atallah is board certified in Hematology and Internal Medicine. He is actively involved in clinical research, co-authoring 113 peer reviewed articles and participating in 13 clinical trials. Dr. Atallah is currently accepting new patients.

Residency

Fairview General Hospital, Cleveland Clinic Health System - Cleveland - OH - Residency in Internal Medicine - (2001

Specialties

Hematology
Oncology

Licenses

Internal Medicine in WI

Board Certifications

Hematology
Internal Medicine

Fellowships

Karmanos Cancer Institute, Wayne State University - Detroit - MI - USA - Fellowship in Hematology/Oncology - (2003-2006)
M. D. Anderson Cancer Center - Houston - TX - Fellowship in Leukemia - (2006-2007)

Hospital Affiliations

Froedtert Memorial Lutheran Hospital
Holy Family Memorial
Froedtert South Inc.

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Clinical Cancer Center - Froedtert Hospital
8800 W. Doyne Ave., Milwaukee, WI 53226
Other Locations
Cancer Center - Moorland Reserve Health Center
4805 S. Moorland Rd., Berlin, WI 53151

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: June 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2026
Intervention Type: Drug, Procedure
Study Drugs: Venetoclax, Liposomal Vincristine
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: Ruxolitinib, BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Study Phase: Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

113 Total Publications

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
Journal: Leukemia & lymphoma
Published: June 12, 2026
Similar Doctors
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology
Referral may be required

Childrens Hospital Of Wisconsin Inc

8915 W Connell Ave, 
Milwaukee, WI 
 (7.4 miles away)
414-257-2424
Languages Spoken:
English
See accepted insurances

Robert Montgomery is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Montgomery is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Blood Clots, Hemophilia A, Hemophilia B, and Bone Marrow Transplant.

Expertise in
15
conditions
Dr. Anita D'souza
Hematology | Oncology
Expertise in
15
conditions
Dr. Anita D'souza
Hematology | Oncology
Referral may be required

Clinical Cancer Center - Froedtert Hospital

8800 W. Doyne Ave., 
Milwaukee, WI 
 (7.3 miles away)
414-805-0505
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Anita D’Souza is a professor of medicine (hematology/oncology). She completed her medical school from Goa Medical College, India where she graduated at the top of her class and was awarded Best Medical Graduate. She completed her internal medicine residency from William Beaumont Hospital in Michigan where she received the Zimmerman Award for Outstanding Clinical Judgment, Leadership, and Integrity. She completed her hematology/oncology fellowship from the Mayo Clinic in Rochester, Minnesota. She is a past recipient of the Daniel McCarty Award for Research Excellent and Women in Science Rising Pioneer Award at MCW. Dr. D'souza is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. D'souza is board certified in Internal Medicine and Medical Oncology And Hematology. Dr. D'souza is currently accepting new patients.

Expertise in
11
conditions
Dr. Binod Dhakal
Hematology | Oncology
Expertise in
11
conditions
Dr. Binod Dhakal
Hematology | Oncology
Referral may be required

Clinical Cancer Center - Froedtert Hospital

8800 W. Doyne Ave., 
Milwaukee, WI 
 (7.3 miles away)
414-805-0505
Languages Spoken:
English, Hindi, Nepali
See accepted insurances
Accepting New Patients
Offers Telehealth

Binod Dhakal, MD, MS, is an associate professor of medicine (hematology and oncology) at the Medical College of Wisconsin, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed internal medicine residency at Saint Francis Hospital, Evanston, IL, and a fellowship in hematology/oncology at the Medical College of Wisconsin, where he also served as a chief fellow. Prior to joining the fellowship, he was an assistant professor of medicine (general internal medicine) at the Medical College in Wisconsin. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; Medical College of Wisconsin Affiliated Hospitals (MCWAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science. His current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials. Dr. Dhakal is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dhakal is currently accepting new patients.

Frequently Asked Questions about Dr. Ehab L. Atallah

How do I make an appointment with Dr. Ehab L. Atallah?

You can book an appointment with Dr. Ehab L. Atallah by calling their office at 414-805-0505. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ehab L. Atallah a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ehab L. Atallah is classified as an Elite expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ehab L. Atallah specialize in?

While Dr. Ehab L. Atallah is a Hematology, they have specific expertise in Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ehab L. Atallah participate in research or clinical trials?

Yes. Dr. Ehab L. Atallah has published 113 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Dr. Ehab L. Atallah's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ehab L. Atallah accept my insurance?

Dr. Ehab L. Atallah accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 414-805-0505 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Atallah's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 10 Advanced Conditions
View All 65 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile